Key result
This review summarizes the progress, advantages, and challenges in the research and design strategies of platelet aggregation inhibitors for thrombotic disorders.
Why the study?
Platelet aggregation is the central event in hemostasis and thrombosis, prompting a summary of research progress and design strategies for platelet aggregation inhibitors.
This review summarizes the progress, advantages, and challenges of different design strategies for platelet aggregation inhibitors.
May guide future antiplatelet design strategies; leaves open clinical validation in prospective trials.
Platelet aggregation is the central event in hemostasis and thrombosis. Up to now, many agents inhibiting platelet aggregation have been approved for the treatment of thrombotic disorders. In this review, we mainly summarized the progress in the research of platelet aggregation inhibitors based on different design strategies. The advantage and challenge of corresponding targets are also discussed in this article. We hope more platelet aggregation inhibitors with efficacy and safety will be discovered in the future.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2019) conducted a review in Thrombotic disorders. Platelet aggregation inhibitors was evaluated. This review summarizes the progress, advantages, and challenges in the research and design strategies of platelet aggregation inhibitors for thrombotic disorders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: